Global Biosimilars Insulin Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Biosimilars Insulin market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
The Global Info Research report includes an overview of the development of the Biosimilars Insulin industry chain, the market status of Type I Diabetes (Insulin Glargine, Insulin Aspart), Type II Diabetes (Insulin Glargine, Insulin Aspart), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Biosimilars Insulin.
Regionally, the report analyzes the Biosimilars Insulin markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Biosimilars Insulin market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Biosimilars Insulin market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Biosimilars Insulin industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Insulin Glargine, Insulin Aspart).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Biosimilars Insulin market.
Regional Analysis: The report involves examining the Biosimilars Insulin market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Biosimilars Insulin market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Biosimilars Insulin:
Company Analysis: Report covers individual Biosimilars Insulin manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Biosimilars Insulin This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Type I Diabetes, Type II Diabetes).
Technology Analysis: Report covers specific technologies relevant to Biosimilars Insulin. It assesses the current state, advancements, and potential future developments in Biosimilars Insulin areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Biosimilars Insulin market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Biosimilars Insulin market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Biosimilars Insulin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Biosimilars Insulin, with price, sales, revenue and global market share of Biosimilars Insulin from 2019 to 2024.
Chapter 3, the Biosimilars Insulin competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilars Insulin breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Biosimilars Insulin market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilars Insulin.
Chapter 14 and 15, to describe Biosimilars Insulin sales channel, distributors, customers, research findings and conclusion.
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
The Global Info Research report includes an overview of the development of the Biosimilars Insulin industry chain, the market status of Type I Diabetes (Insulin Glargine, Insulin Aspart), Type II Diabetes (Insulin Glargine, Insulin Aspart), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Biosimilars Insulin.
Regionally, the report analyzes the Biosimilars Insulin markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Biosimilars Insulin market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Biosimilars Insulin market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Biosimilars Insulin industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Insulin Glargine, Insulin Aspart).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Biosimilars Insulin market.
Regional Analysis: The report involves examining the Biosimilars Insulin market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Biosimilars Insulin market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Biosimilars Insulin:
Company Analysis: Report covers individual Biosimilars Insulin manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Biosimilars Insulin This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Type I Diabetes, Type II Diabetes).
Technology Analysis: Report covers specific technologies relevant to Biosimilars Insulin. It assesses the current state, advancements, and potential future developments in Biosimilars Insulin areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Biosimilars Insulin market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Biosimilars Insulin market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Insulin Glargine
- Insulin Aspart
- Insulin Lispro
- Other
- Type I Diabetes
- Type II Diabetes
- Eli Lilly
- Boehringer Ingelheim
- Biocon/Mylan
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao
- United Laboratories
- Sanofi
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Biosimilars Insulin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Biosimilars Insulin, with price, sales, revenue and global market share of Biosimilars Insulin from 2019 to 2024.
Chapter 3, the Biosimilars Insulin competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilars Insulin breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Biosimilars Insulin market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilars Insulin.
Chapter 14 and 15, to describe Biosimilars Insulin sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Biosimilars Insulin
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Biosimilars Insulin Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Insulin Glargine
1.3.3 Insulin Aspart
1.3.4 Insulin Lispro
1.3.5 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Biosimilars Insulin Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Type I Diabetes
1.4.3 Type II Diabetes
1.5 Global Biosimilars Insulin Market Size & Forecast
1.5.1 Global Biosimilars Insulin Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Biosimilars Insulin Sales Quantity (2019-2030)
1.5.3 Global Biosimilars Insulin Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business
2.1.3 Eli Lilly Biosimilars Insulin Product and Services
2.1.4 Eli Lilly Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Eli Lilly Recent Developments/Updates
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Biosimilars Insulin Product and Services
2.2.4 Boehringer Ingelheim Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Boehringer Ingelheim Recent Developments/Updates
2.3 Biocon/Mylan
2.3.1 Biocon/Mylan Details
2.3.2 Biocon/Mylan Major Business
2.3.3 Biocon/Mylan Biosimilars Insulin Product and Services
2.3.4 Biocon/Mylan Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Biocon/Mylan Recent Developments/Updates
2.4 Gan & Lee Pharmaceuticals
2.4.1 Gan & Lee Pharmaceuticals Details
2.4.2 Gan & Lee Pharmaceuticals Major Business
2.4.3 Gan & Lee Pharmaceuticals Biosimilars Insulin Product and Services
2.4.4 Gan & Lee Pharmaceuticals Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
2.5 Tonghua Dongbao
2.5.1 Tonghua Dongbao Details
2.5.2 Tonghua Dongbao Major Business
2.5.3 Tonghua Dongbao Biosimilars Insulin Product and Services
2.5.4 Tonghua Dongbao Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Tonghua Dongbao Recent Developments/Updates
2.6 United Laboratories
2.6.1 United Laboratories Details
2.6.2 United Laboratories Major Business
2.6.3 United Laboratories Biosimilars Insulin Product and Services
2.6.4 United Laboratories Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 United Laboratories Recent Developments/Updates
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Biosimilars Insulin Product and Services
2.7.4 Sanofi Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Sanofi Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: BIOSIMILARS INSULIN BY MANUFACTURER
3.1 Global Biosimilars Insulin Sales Quantity by Manufacturer (2019-2024)
3.2 Global Biosimilars Insulin Revenue by Manufacturer (2019-2024)
3.3 Global Biosimilars Insulin Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Biosimilars Insulin by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Biosimilars Insulin Manufacturer Market Share in 2023
3.4.2 Top 6 Biosimilars Insulin Manufacturer Market Share in 2023
3.5 Biosimilars Insulin Market: Overall Company Footprint Analysis
3.5.1 Biosimilars Insulin Market: Region Footprint
3.5.2 Biosimilars Insulin Market: Company Product Type Footprint
3.5.3 Biosimilars Insulin Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Biosimilars Insulin Market Size by Region
4.1.1 Global Biosimilars Insulin Sales Quantity by Region (2019-2030)
4.1.2 Global Biosimilars Insulin Consumption Value by Region (2019-2030)
4.1.3 Global Biosimilars Insulin Average Price by Region (2019-2030)
4.2 North America Biosimilars Insulin Consumption Value (2019-2030)
4.3 Europe Biosimilars Insulin Consumption Value (2019-2030)
4.4 Asia-Pacific Biosimilars Insulin Consumption Value (2019-2030)
4.5 South America Biosimilars Insulin Consumption Value (2019-2030)
4.6 Middle East and Africa Biosimilars Insulin Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Biosimilars Insulin Sales Quantity by Type (2019-2030)
5.2 Global Biosimilars Insulin Consumption Value by Type (2019-2030)
5.3 Global Biosimilars Insulin Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Biosimilars Insulin Sales Quantity by Application (2019-2030)
6.2 Global Biosimilars Insulin Consumption Value by Application (2019-2030)
6.3 Global Biosimilars Insulin Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Biosimilars Insulin Sales Quantity by Type (2019-2030)
7.2 North America Biosimilars Insulin Sales Quantity by Application (2019-2030)
7.3 North America Biosimilars Insulin Market Size by Country
7.3.1 North America Biosimilars Insulin Sales Quantity by Country (2019-2030)
7.3.2 North America Biosimilars Insulin Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Biosimilars Insulin Sales Quantity by Type (2019-2030)
8.2 Europe Biosimilars Insulin Sales Quantity by Application (2019-2030)
8.3 Europe Biosimilars Insulin Market Size by Country
8.3.1 Europe Biosimilars Insulin Sales Quantity by Country (2019-2030)
8.3.2 Europe Biosimilars Insulin Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Biosimilars Insulin Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Biosimilars Insulin Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Biosimilars Insulin Market Size by Region
9.3.1 Asia-Pacific Biosimilars Insulin Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Biosimilars Insulin Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Biosimilars Insulin Sales Quantity by Type (2019-2030)
10.2 South America Biosimilars Insulin Sales Quantity by Application (2019-2030)
10.3 South America Biosimilars Insulin Market Size by Country
10.3.1 South America Biosimilars Insulin Sales Quantity by Country (2019-2030)
10.3.2 South America Biosimilars Insulin Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Biosimilars Insulin Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Biosimilars Insulin Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Biosimilars Insulin Market Size by Country
11.3.1 Middle East & Africa Biosimilars Insulin Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Biosimilars Insulin Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Biosimilars Insulin Market Drivers
12.2 Biosimilars Insulin Market Restraints
12.3 Biosimilars Insulin Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Biosimilars Insulin and Key Manufacturers
13.2 Manufacturing Costs Percentage of Biosimilars Insulin
13.3 Biosimilars Insulin Production Process
13.4 Biosimilars Insulin Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Biosimilars Insulin Typical Distributors
14.3 Biosimilars Insulin Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Biosimilars Insulin
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Biosimilars Insulin Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Insulin Glargine
1.3.3 Insulin Aspart
1.3.4 Insulin Lispro
1.3.5 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Biosimilars Insulin Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Type I Diabetes
1.4.3 Type II Diabetes
1.5 Global Biosimilars Insulin Market Size & Forecast
1.5.1 Global Biosimilars Insulin Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Biosimilars Insulin Sales Quantity (2019-2030)
1.5.3 Global Biosimilars Insulin Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business
2.1.3 Eli Lilly Biosimilars Insulin Product and Services
2.1.4 Eli Lilly Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Eli Lilly Recent Developments/Updates
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Biosimilars Insulin Product and Services
2.2.4 Boehringer Ingelheim Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Boehringer Ingelheim Recent Developments/Updates
2.3 Biocon/Mylan
2.3.1 Biocon/Mylan Details
2.3.2 Biocon/Mylan Major Business
2.3.3 Biocon/Mylan Biosimilars Insulin Product and Services
2.3.4 Biocon/Mylan Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Biocon/Mylan Recent Developments/Updates
2.4 Gan & Lee Pharmaceuticals
2.4.1 Gan & Lee Pharmaceuticals Details
2.4.2 Gan & Lee Pharmaceuticals Major Business
2.4.3 Gan & Lee Pharmaceuticals Biosimilars Insulin Product and Services
2.4.4 Gan & Lee Pharmaceuticals Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
2.5 Tonghua Dongbao
2.5.1 Tonghua Dongbao Details
2.5.2 Tonghua Dongbao Major Business
2.5.3 Tonghua Dongbao Biosimilars Insulin Product and Services
2.5.4 Tonghua Dongbao Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Tonghua Dongbao Recent Developments/Updates
2.6 United Laboratories
2.6.1 United Laboratories Details
2.6.2 United Laboratories Major Business
2.6.3 United Laboratories Biosimilars Insulin Product and Services
2.6.4 United Laboratories Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 United Laboratories Recent Developments/Updates
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Biosimilars Insulin Product and Services
2.7.4 Sanofi Biosimilars Insulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Sanofi Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: BIOSIMILARS INSULIN BY MANUFACTURER
3.1 Global Biosimilars Insulin Sales Quantity by Manufacturer (2019-2024)
3.2 Global Biosimilars Insulin Revenue by Manufacturer (2019-2024)
3.3 Global Biosimilars Insulin Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Biosimilars Insulin by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Biosimilars Insulin Manufacturer Market Share in 2023
3.4.2 Top 6 Biosimilars Insulin Manufacturer Market Share in 2023
3.5 Biosimilars Insulin Market: Overall Company Footprint Analysis
3.5.1 Biosimilars Insulin Market: Region Footprint
3.5.2 Biosimilars Insulin Market: Company Product Type Footprint
3.5.3 Biosimilars Insulin Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Biosimilars Insulin Market Size by Region
4.1.1 Global Biosimilars Insulin Sales Quantity by Region (2019-2030)
4.1.2 Global Biosimilars Insulin Consumption Value by Region (2019-2030)
4.1.3 Global Biosimilars Insulin Average Price by Region (2019-2030)
4.2 North America Biosimilars Insulin Consumption Value (2019-2030)
4.3 Europe Biosimilars Insulin Consumption Value (2019-2030)
4.4 Asia-Pacific Biosimilars Insulin Consumption Value (2019-2030)
4.5 South America Biosimilars Insulin Consumption Value (2019-2030)
4.6 Middle East and Africa Biosimilars Insulin Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Biosimilars Insulin Sales Quantity by Type (2019-2030)
5.2 Global Biosimilars Insulin Consumption Value by Type (2019-2030)
5.3 Global Biosimilars Insulin Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Biosimilars Insulin Sales Quantity by Application (2019-2030)
6.2 Global Biosimilars Insulin Consumption Value by Application (2019-2030)
6.3 Global Biosimilars Insulin Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Biosimilars Insulin Sales Quantity by Type (2019-2030)
7.2 North America Biosimilars Insulin Sales Quantity by Application (2019-2030)
7.3 North America Biosimilars Insulin Market Size by Country
7.3.1 North America Biosimilars Insulin Sales Quantity by Country (2019-2030)
7.3.2 North America Biosimilars Insulin Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Biosimilars Insulin Sales Quantity by Type (2019-2030)
8.2 Europe Biosimilars Insulin Sales Quantity by Application (2019-2030)
8.3 Europe Biosimilars Insulin Market Size by Country
8.3.1 Europe Biosimilars Insulin Sales Quantity by Country (2019-2030)
8.3.2 Europe Biosimilars Insulin Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Biosimilars Insulin Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Biosimilars Insulin Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Biosimilars Insulin Market Size by Region
9.3.1 Asia-Pacific Biosimilars Insulin Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Biosimilars Insulin Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Biosimilars Insulin Sales Quantity by Type (2019-2030)
10.2 South America Biosimilars Insulin Sales Quantity by Application (2019-2030)
10.3 South America Biosimilars Insulin Market Size by Country
10.3.1 South America Biosimilars Insulin Sales Quantity by Country (2019-2030)
10.3.2 South America Biosimilars Insulin Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Biosimilars Insulin Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Biosimilars Insulin Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Biosimilars Insulin Market Size by Country
11.3.1 Middle East & Africa Biosimilars Insulin Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Biosimilars Insulin Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Biosimilars Insulin Market Drivers
12.2 Biosimilars Insulin Market Restraints
12.3 Biosimilars Insulin Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Biosimilars Insulin and Key Manufacturers
13.2 Manufacturing Costs Percentage of Biosimilars Insulin
13.3 Biosimilars Insulin Production Process
13.4 Biosimilars Insulin Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Biosimilars Insulin Typical Distributors
14.3 Biosimilars Insulin Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
.
Table 1. Global Biosimilars Insulin Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Biosimilars Insulin Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 4. Eli Lilly Major Business
Table 5. Eli Lilly Biosimilars Insulin Product and Services
Table 6. Eli Lilly Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Eli Lilly Recent Developments/Updates
Table 8. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 9. Boehringer Ingelheim Major Business
Table 10. Boehringer Ingelheim Biosimilars Insulin Product and Services
Table 11. Boehringer Ingelheim Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Boehringer Ingelheim Recent Developments/Updates
Table 13. Biocon/Mylan Basic Information, Manufacturing Base and Competitors
Table 14. Biocon/Mylan Major Business
Table 15. Biocon/Mylan Biosimilars Insulin Product and Services
Table 16. Biocon/Mylan Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Biocon/Mylan Recent Developments/Updates
Table 18. Gan & Lee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Gan & Lee Pharmaceuticals Major Business
Table 20. Gan & Lee Pharmaceuticals Biosimilars Insulin Product and Services
Table 21. Gan & Lee Pharmaceuticals Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Gan & Lee Pharmaceuticals Recent Developments/Updates
Table 23. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
Table 24. Tonghua Dongbao Major Business
Table 25. Tonghua Dongbao Biosimilars Insulin Product and Services
Table 26. Tonghua Dongbao Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Tonghua Dongbao Recent Developments/Updates
Table 28. United Laboratories Basic Information, Manufacturing Base and Competitors
Table 29. United Laboratories Major Business
Table 30. United Laboratories Biosimilars Insulin Product and Services
Table 31. United Laboratories Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. United Laboratories Recent Developments/Updates
Table 33. Sanofi Basic Information, Manufacturing Base and Competitors
Table 34. Sanofi Major Business
Table 35. Sanofi Biosimilars Insulin Product and Services
Table 36. Sanofi Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Sanofi Recent Developments/Updates
Table 38. Global Biosimilars Insulin Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 39. Global Biosimilars Insulin Revenue by Manufacturer (2019-2024) & (USD Million)
Table 40. Global Biosimilars Insulin Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 41. Market Position of Manufacturers in Biosimilars Insulin, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 42. Head Office and Biosimilars Insulin Production Site of Key Manufacturer
Table 43. Biosimilars Insulin Market: Company Product Type Footprint
Table 44. Biosimilars Insulin Market: Company Product Application Footprint
Table 45. Biosimilars Insulin New Market Entrants and Barriers to Market Entry
Table 46. Biosimilars Insulin Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global Biosimilars Insulin Sales Quantity by Region (2019-2024) & (K Units)
Table 48. Global Biosimilars Insulin Sales Quantity by Region (2025-2030) & (K Units)
Table 49. Global Biosimilars Insulin Consumption Value by Region (2019-2024) & (USD Million)
Table 50. Global Biosimilars Insulin Consumption Value by Region (2025-2030) & (USD Million)
Table 51. Global Biosimilars Insulin Average Price by Region (2019-2024) & (USD/Unit)
Table 52. Global Biosimilars Insulin Average Price by Region (2025-2030) & (USD/Unit)
Table 53. Global Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 54. Global Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 55. Global Biosimilars Insulin Consumption Value by Type (2019-2024) & (USD Million)
Table 56. Global Biosimilars Insulin Consumption Value by Type (2025-2030) & (USD Million)
Table 57. Global Biosimilars Insulin Average Price by Type (2019-2024) & (USD/Unit)
Table 58. Global Biosimilars Insulin Average Price by Type (2025-2030) & (USD/Unit)
Table 59. Global Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 60. Global Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 61. Global Biosimilars Insulin Consumption Value by Application (2019-2024) & (USD Million)
Table 62. Global Biosimilars Insulin Consumption Value by Application (2025-2030) & (USD Million)
Table 63. Global Biosimilars Insulin Average Price by Application (2019-2024) & (USD/Unit)
Table 64. Global Biosimilars Insulin Average Price by Application (2025-2030) & (USD/Unit)
Table 65. North America Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 66. North America Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 67. North America Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 68. North America Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 69. North America Biosimilars Insulin Sales Quantity by Country (2019-2024) & (K Units)
Table 70. North America Biosimilars Insulin Sales Quantity by Country (2025-2030) & (K Units)
Table 71. North America Biosimilars Insulin Consumption Value by Country (2019-2024) & (USD Million)
Table 72. North America Biosimilars Insulin Consumption Value by Country (2025-2030) & (USD Million)
Table 73. Europe Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 74. Europe Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 75. Europe Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 76. Europe Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 77. Europe Biosimilars Insulin Sales Quantity by Country (2019-2024) & (K Units)
Table 78. Europe Biosimilars Insulin Sales Quantity by Country (2025-2030) & (K Units)
Table 79. Europe Biosimilars Insulin Consumption Value by Country (2019-2024) & (USD Million)
Table 80. Europe Biosimilars Insulin Consumption Value by Country (2025-2030) & (USD Million)
Table 81. Asia-Pacific Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 82. Asia-Pacific Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 83. Asia-Pacific Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 84. Asia-Pacific Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 85. Asia-Pacific Biosimilars Insulin Sales Quantity by Region (2019-2024) & (K Units)
Table 86. Asia-Pacific Biosimilars Insulin Sales Quantity by Region (2025-2030) & (K Units)
Table 87. Asia-Pacific Biosimilars Insulin Consumption Value by Region (2019-2024) & (USD Million)
Table 88. Asia-Pacific Biosimilars Insulin Consumption Value by Region (2025-2030) & (USD Million)
Table 89. South America Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 90. South America Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 91. South America Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 92. South America Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 93. South America Biosimilars Insulin Sales Quantity by Country (2019-2024) & (K Units)
Table 94. South America Biosimilars Insulin Sales Quantity by Country (2025-2030) & (K Units)
Table 95. South America Biosimilars Insulin Consumption Value by Country (2019-2024) & (USD Million)
Table 96. South America Biosimilars Insulin Consumption Value by Country (2025-2030) & (USD Million)
Table 97. Middle East & Africa Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 98. Middle East & Africa Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 99. Middle East & Africa Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 100. Middle East & Africa Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 101. Middle East & Africa Biosimilars Insulin Sales Quantity by Region (2019-2024) & (K Units)
Table 102. Middle East & Africa Biosimilars Insulin Sales Quantity by Region (2025-2030) & (K Units)
Table 103. Middle East & Africa Biosimilars Insulin Consumption Value by Region (2019-2024) & (USD Million)
Table 104. Middle East & Africa Biosimilars Insulin Consumption Value by Region (2025-2030) & (USD Million)
Table 105. Biosimilars Insulin Raw Material
Table 106. Key Manufacturers of Biosimilars Insulin Raw Materials
Table 107. Biosimilars Insulin Typical Distributors
Table 108. Biosimilars Insulin Typical Customers
.
Table 1. Global Biosimilars Insulin Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Biosimilars Insulin Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 4. Eli Lilly Major Business
Table 5. Eli Lilly Biosimilars Insulin Product and Services
Table 6. Eli Lilly Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Eli Lilly Recent Developments/Updates
Table 8. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 9. Boehringer Ingelheim Major Business
Table 10. Boehringer Ingelheim Biosimilars Insulin Product and Services
Table 11. Boehringer Ingelheim Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Boehringer Ingelheim Recent Developments/Updates
Table 13. Biocon/Mylan Basic Information, Manufacturing Base and Competitors
Table 14. Biocon/Mylan Major Business
Table 15. Biocon/Mylan Biosimilars Insulin Product and Services
Table 16. Biocon/Mylan Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Biocon/Mylan Recent Developments/Updates
Table 18. Gan & Lee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Gan & Lee Pharmaceuticals Major Business
Table 20. Gan & Lee Pharmaceuticals Biosimilars Insulin Product and Services
Table 21. Gan & Lee Pharmaceuticals Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Gan & Lee Pharmaceuticals Recent Developments/Updates
Table 23. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
Table 24. Tonghua Dongbao Major Business
Table 25. Tonghua Dongbao Biosimilars Insulin Product and Services
Table 26. Tonghua Dongbao Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Tonghua Dongbao Recent Developments/Updates
Table 28. United Laboratories Basic Information, Manufacturing Base and Competitors
Table 29. United Laboratories Major Business
Table 30. United Laboratories Biosimilars Insulin Product and Services
Table 31. United Laboratories Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. United Laboratories Recent Developments/Updates
Table 33. Sanofi Basic Information, Manufacturing Base and Competitors
Table 34. Sanofi Major Business
Table 35. Sanofi Biosimilars Insulin Product and Services
Table 36. Sanofi Biosimilars Insulin Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Sanofi Recent Developments/Updates
Table 38. Global Biosimilars Insulin Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 39. Global Biosimilars Insulin Revenue by Manufacturer (2019-2024) & (USD Million)
Table 40. Global Biosimilars Insulin Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 41. Market Position of Manufacturers in Biosimilars Insulin, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 42. Head Office and Biosimilars Insulin Production Site of Key Manufacturer
Table 43. Biosimilars Insulin Market: Company Product Type Footprint
Table 44. Biosimilars Insulin Market: Company Product Application Footprint
Table 45. Biosimilars Insulin New Market Entrants and Barriers to Market Entry
Table 46. Biosimilars Insulin Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global Biosimilars Insulin Sales Quantity by Region (2019-2024) & (K Units)
Table 48. Global Biosimilars Insulin Sales Quantity by Region (2025-2030) & (K Units)
Table 49. Global Biosimilars Insulin Consumption Value by Region (2019-2024) & (USD Million)
Table 50. Global Biosimilars Insulin Consumption Value by Region (2025-2030) & (USD Million)
Table 51. Global Biosimilars Insulin Average Price by Region (2019-2024) & (USD/Unit)
Table 52. Global Biosimilars Insulin Average Price by Region (2025-2030) & (USD/Unit)
Table 53. Global Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 54. Global Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 55. Global Biosimilars Insulin Consumption Value by Type (2019-2024) & (USD Million)
Table 56. Global Biosimilars Insulin Consumption Value by Type (2025-2030) & (USD Million)
Table 57. Global Biosimilars Insulin Average Price by Type (2019-2024) & (USD/Unit)
Table 58. Global Biosimilars Insulin Average Price by Type (2025-2030) & (USD/Unit)
Table 59. Global Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 60. Global Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 61. Global Biosimilars Insulin Consumption Value by Application (2019-2024) & (USD Million)
Table 62. Global Biosimilars Insulin Consumption Value by Application (2025-2030) & (USD Million)
Table 63. Global Biosimilars Insulin Average Price by Application (2019-2024) & (USD/Unit)
Table 64. Global Biosimilars Insulin Average Price by Application (2025-2030) & (USD/Unit)
Table 65. North America Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 66. North America Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 67. North America Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 68. North America Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 69. North America Biosimilars Insulin Sales Quantity by Country (2019-2024) & (K Units)
Table 70. North America Biosimilars Insulin Sales Quantity by Country (2025-2030) & (K Units)
Table 71. North America Biosimilars Insulin Consumption Value by Country (2019-2024) & (USD Million)
Table 72. North America Biosimilars Insulin Consumption Value by Country (2025-2030) & (USD Million)
Table 73. Europe Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 74. Europe Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 75. Europe Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 76. Europe Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 77. Europe Biosimilars Insulin Sales Quantity by Country (2019-2024) & (K Units)
Table 78. Europe Biosimilars Insulin Sales Quantity by Country (2025-2030) & (K Units)
Table 79. Europe Biosimilars Insulin Consumption Value by Country (2019-2024) & (USD Million)
Table 80. Europe Biosimilars Insulin Consumption Value by Country (2025-2030) & (USD Million)
Table 81. Asia-Pacific Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 82. Asia-Pacific Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 83. Asia-Pacific Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 84. Asia-Pacific Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 85. Asia-Pacific Biosimilars Insulin Sales Quantity by Region (2019-2024) & (K Units)
Table 86. Asia-Pacific Biosimilars Insulin Sales Quantity by Region (2025-2030) & (K Units)
Table 87. Asia-Pacific Biosimilars Insulin Consumption Value by Region (2019-2024) & (USD Million)
Table 88. Asia-Pacific Biosimilars Insulin Consumption Value by Region (2025-2030) & (USD Million)
Table 89. South America Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 90. South America Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 91. South America Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 92. South America Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 93. South America Biosimilars Insulin Sales Quantity by Country (2019-2024) & (K Units)
Table 94. South America Biosimilars Insulin Sales Quantity by Country (2025-2030) & (K Units)
Table 95. South America Biosimilars Insulin Consumption Value by Country (2019-2024) & (USD Million)
Table 96. South America Biosimilars Insulin Consumption Value by Country (2025-2030) & (USD Million)
Table 97. Middle East & Africa Biosimilars Insulin Sales Quantity by Type (2019-2024) & (K Units)
Table 98. Middle East & Africa Biosimilars Insulin Sales Quantity by Type (2025-2030) & (K Units)
Table 99. Middle East & Africa Biosimilars Insulin Sales Quantity by Application (2019-2024) & (K Units)
Table 100. Middle East & Africa Biosimilars Insulin Sales Quantity by Application (2025-2030) & (K Units)
Table 101. Middle East & Africa Biosimilars Insulin Sales Quantity by Region (2019-2024) & (K Units)
Table 102. Middle East & Africa Biosimilars Insulin Sales Quantity by Region (2025-2030) & (K Units)
Table 103. Middle East & Africa Biosimilars Insulin Consumption Value by Region (2019-2024) & (USD Million)
Table 104. Middle East & Africa Biosimilars Insulin Consumption Value by Region (2025-2030) & (USD Million)
Table 105. Biosimilars Insulin Raw Material
Table 106. Key Manufacturers of Biosimilars Insulin Raw Materials
Table 107. Biosimilars Insulin Typical Distributors
Table 108. Biosimilars Insulin Typical Customers
LIST OF FIGURES
.
Figure 1. Biosimilars Insulin Picture
Figure 2. Global Biosimilars Insulin Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Biosimilars Insulin Consumption Value Market Share by Type in 2023
Figure 4. Insulin Glargine Examples
Figure 5. Insulin Aspart Examples
Figure 6. Insulin Lispro Examples
Figure 7. Other Examples
Figure 8. Global Biosimilars Insulin Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 9. Global Biosimilars Insulin Consumption Value Market Share by Application in 2023
Figure 10. Type I Diabetes Examples
Figure 11. Type II Diabetes Examples
Figure 12. Global Biosimilars Insulin Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Biosimilars Insulin Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Biosimilars Insulin Sales Quantity (2019-2030) & (K Units)
Figure 15. Global Biosimilars Insulin Average Price (2019-2030) & (USD/Unit)
Figure 16. Global Biosimilars Insulin Sales Quantity Market Share by Manufacturer in 2023
Figure 17. Global Biosimilars Insulin Consumption Value Market Share by Manufacturer in 2023
Figure 18. Producer Shipments of Biosimilars Insulin by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 19. Top 3 Biosimilars Insulin Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Top 6 Biosimilars Insulin Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Global Biosimilars Insulin Sales Quantity Market Share by Region (2019-2030)
Figure 22. Global Biosimilars Insulin Consumption Value Market Share by Region (2019-2030)
Figure 23. North America Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 24. Europe Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 25. Asia-Pacific Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 26. South America Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 27. Middle East & Africa Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 28. Global Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 29. Global Biosimilars Insulin Consumption Value Market Share by Type (2019-2030)
Figure 30. Global Biosimilars Insulin Average Price by Type (2019-2030) & (USD/Unit)
Figure 31. Global Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 32. Global Biosimilars Insulin Consumption Value Market Share by Application (2019-2030)
Figure 33. Global Biosimilars Insulin Average Price by Application (2019-2030) & (USD/Unit)
Figure 34. North America Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 35. North America Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 36. North America Biosimilars Insulin Sales Quantity Market Share by Country (2019-2030)
Figure 37. North America Biosimilars Insulin Consumption Value Market Share by Country (2019-2030)
Figure 38. United States Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Canada Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Mexico Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Europe Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 42. Europe Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 43. Europe Biosimilars Insulin Sales Quantity Market Share by Country (2019-2030)
Figure 44. Europe Biosimilars Insulin Consumption Value Market Share by Country (2019-2030)
Figure 45. Germany Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. France Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. United Kingdom Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Russia Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Italy Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Asia-Pacific Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 51. Asia-Pacific Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 52. Asia-Pacific Biosimilars Insulin Sales Quantity Market Share by Region (2019-2030)
Figure 53. Asia-Pacific Biosimilars Insulin Consumption Value Market Share by Region (2019-2030)
Figure 54. China Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Japan Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Korea Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. India Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Southeast Asia Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Australia Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. South America Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 61. South America Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 62. South America Biosimilars Insulin Sales Quantity Market Share by Country (2019-2030)
Figure 63. South America Biosimilars Insulin Consumption Value Market Share by Country (2019-2030)
Figure 64. Brazil Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Argentina Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Middle East & Africa Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 67. Middle East & Africa Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 68. Middle East & Africa Biosimilars Insulin Sales Quantity Market Share by Region (2019-2030)
Figure 69. Middle East & Africa Biosimilars Insulin Consumption Value Market Share by Region (2019-2030)
Figure 70. Turkey Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Egypt Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Saudi Arabia Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. South Africa Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Biosimilars Insulin Market Drivers
Figure 75. Biosimilars Insulin Market Restraints
Figure 76. Biosimilars Insulin Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Biosimilars Insulin in 2023
Figure 79. Manufacturing Process Analysis of Biosimilars Insulin
Figure 80. Biosimilars Insulin Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
.
Figure 1. Biosimilars Insulin Picture
Figure 2. Global Biosimilars Insulin Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Biosimilars Insulin Consumption Value Market Share by Type in 2023
Figure 4. Insulin Glargine Examples
Figure 5. Insulin Aspart Examples
Figure 6. Insulin Lispro Examples
Figure 7. Other Examples
Figure 8. Global Biosimilars Insulin Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 9. Global Biosimilars Insulin Consumption Value Market Share by Application in 2023
Figure 10. Type I Diabetes Examples
Figure 11. Type II Diabetes Examples
Figure 12. Global Biosimilars Insulin Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Biosimilars Insulin Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Biosimilars Insulin Sales Quantity (2019-2030) & (K Units)
Figure 15. Global Biosimilars Insulin Average Price (2019-2030) & (USD/Unit)
Figure 16. Global Biosimilars Insulin Sales Quantity Market Share by Manufacturer in 2023
Figure 17. Global Biosimilars Insulin Consumption Value Market Share by Manufacturer in 2023
Figure 18. Producer Shipments of Biosimilars Insulin by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 19. Top 3 Biosimilars Insulin Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Top 6 Biosimilars Insulin Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Global Biosimilars Insulin Sales Quantity Market Share by Region (2019-2030)
Figure 22. Global Biosimilars Insulin Consumption Value Market Share by Region (2019-2030)
Figure 23. North America Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 24. Europe Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 25. Asia-Pacific Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 26. South America Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 27. Middle East & Africa Biosimilars Insulin Consumption Value (2019-2030) & (USD Million)
Figure 28. Global Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 29. Global Biosimilars Insulin Consumption Value Market Share by Type (2019-2030)
Figure 30. Global Biosimilars Insulin Average Price by Type (2019-2030) & (USD/Unit)
Figure 31. Global Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 32. Global Biosimilars Insulin Consumption Value Market Share by Application (2019-2030)
Figure 33. Global Biosimilars Insulin Average Price by Application (2019-2030) & (USD/Unit)
Figure 34. North America Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 35. North America Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 36. North America Biosimilars Insulin Sales Quantity Market Share by Country (2019-2030)
Figure 37. North America Biosimilars Insulin Consumption Value Market Share by Country (2019-2030)
Figure 38. United States Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Canada Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Mexico Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Europe Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 42. Europe Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 43. Europe Biosimilars Insulin Sales Quantity Market Share by Country (2019-2030)
Figure 44. Europe Biosimilars Insulin Consumption Value Market Share by Country (2019-2030)
Figure 45. Germany Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. France Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. United Kingdom Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Russia Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Italy Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Asia-Pacific Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 51. Asia-Pacific Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 52. Asia-Pacific Biosimilars Insulin Sales Quantity Market Share by Region (2019-2030)
Figure 53. Asia-Pacific Biosimilars Insulin Consumption Value Market Share by Region (2019-2030)
Figure 54. China Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Japan Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Korea Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. India Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Southeast Asia Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Australia Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. South America Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 61. South America Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 62. South America Biosimilars Insulin Sales Quantity Market Share by Country (2019-2030)
Figure 63. South America Biosimilars Insulin Consumption Value Market Share by Country (2019-2030)
Figure 64. Brazil Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Argentina Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Middle East & Africa Biosimilars Insulin Sales Quantity Market Share by Type (2019-2030)
Figure 67. Middle East & Africa Biosimilars Insulin Sales Quantity Market Share by Application (2019-2030)
Figure 68. Middle East & Africa Biosimilars Insulin Sales Quantity Market Share by Region (2019-2030)
Figure 69. Middle East & Africa Biosimilars Insulin Consumption Value Market Share by Region (2019-2030)
Figure 70. Turkey Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Egypt Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Saudi Arabia Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. South Africa Biosimilars Insulin Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Biosimilars Insulin Market Drivers
Figure 75. Biosimilars Insulin Market Restraints
Figure 76. Biosimilars Insulin Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Biosimilars Insulin in 2023
Figure 79. Manufacturing Process Analysis of Biosimilars Insulin
Figure 80. Biosimilars Insulin Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
More Publications
Global G-CSF Biosimilars Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
US$ 3,480.00
November 2024
115 pages
Global HGH Biosimilars Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
US$ 3,480.00
November 2024
109 pages
Global Biosimilar Supply, Demand and Key Producers, 2026-2032
US$ 4,480.00
January 2026
111 pages
Global Monoclonal Antibodies (mAbs) Biosimilars Market 2026 by Company, Regions, Type and Application, Forecast to 2032
US$ 3,480.00
May 2026
191 pages
Global Human Insulin Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
US$ 3,480.00
June 2024
114 pages
